Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies
Sandra D’Angelo, MD, and Nam Bui, MD, examine synovial sarcoma's distinct molecular signature driven by the SS18-SSX fusion gene, highlighting critical unmet treatment needs that led to the groundbreaking approval of afami-cel, a MAGE-A4-targeted TCR therapy demonstrating promising efficacy in the SPEARHEAD-1 trial, potentially paving the way for broader adoption of TCR-based therapies in solid tumors.
EP. 1: Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis
December 24th 2024Panelists discuss how synovial sarcoma is a rare soft-tissue cancer characterized by its unique SS18::SSX fusion oncogene transcript, which distinguishes it from other sarcomas and drives its aggressive behavior through altered epigenetic regulation, despite its misleading name suggesting origin in synovial tissue.
